TY - JOUR T1 - SARS-CoV-2 seroprevalence in the city of Hyderabad, India in early 2021 JF - medRxiv DO - 10.1101/2021.07.18.21260555 SP - 2021.07.18.21260555 AU - Avula Laxmaiah AU - Nalam Madhusudhan Rao AU - N. Arlappa AU - Jagjeevan Babu AU - P. Uday Kumar AU - Priya Singh AU - Deepak Sharma AU - V. Mahesh Anumalla AU - T. Santhosh Kumar AU - R. Sabarinathan AU - M. Santhos Kumar AU - R. Ananthan AU - P.P.S. Blessy AU - D. Chandra Kumar AU - P. Devaraj AU - S. Devendra AU - M. Mahesh Kumar AU - Indrapal I. Meshram AU - B. Naveen Kumar AU - Paras Sharma AU - P. Raghavendra AU - P. Raghu AU - K. Rajender Rao AU - P. Ravindranadh AU - B. Santosh Kumar AU - Sarika AU - J. Srinivasa Rao AU - M.V. Surekha AU - F. Sylvia AU - Deepak Kumar AU - G. Subba Rao AU - Karthik Bharadwaj Tallapaka AU - Divya Tej Sowpati AU - Surabhi Srivastava AU - Manoj Murekhar AU - Rajkumar Hemalatha AU - Rakesh K Mishra Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/22/2021.07.18.21260555.abstract N2 - Background COVID-19 emerged as a global pandemic in 2020, rapidly spreading to most parts of the world. The proportion of infected individuals in a population can be reliably estimated via sero-surveillance, making it a valuable tool for planning control measures. We conducted a serosurvey study to investigate SARS-CoV-2 seroprevalence in the urban population of Hyderabad at the end of the first wave of infections.Methods The cross-sectional survey conducted in January 2021 included males and females aged 10 years and above, selected by multi-stage random sampling. 9363 samples were collected from 30 wards distributed over 6 zones of Hyderabad and tested for antibodies against SARS-CoV-2 nucleocapsid antigen.Results Overall seropositivity was 54.2%, ranging from 50-60% in most wards. Highest exposure appeared to be among 30-39y and 50-59y olds, with women showing greater seropositivity. Seropositivity increased with family size, with only marginal differences among people with varying levels of education. Seroprevalence was significantly lower among smokers. Only 11% of the survey subjects reported any COVID-19 symptoms, while 17% had appeared for Covid testing.Conclusion Over half the city’s population was infected within a year of onset of the pandemic. However, ∼46% people were still susceptible, contributing to subsequent waves of infection.Highlights⍰ National level serosurveys under-estimate localised prevalence in dense urban areas⍰ SARS-CoV-2 seroprevalence in Hyderabad city was 54.2% after the first wave⍰ A large proportion of the population remains at risk over a year into the pandemicCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by institutional funding of ICMR-NIN and CSIR-CCMB, with generous support from Bharath Biotech Pvt. Limited. Bharath Biotech Pvt. Limited was involved in procurement & supply of the test kits and had no role in design of the study, data handling, sample analysis or in the preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was granted by the IEC-NIN - Institutional Ethical Committee, National Institute of Nutrition (ICMR), Ministry of Health and Family Welfare, Govt of India on 1st Dec 2020 (NIN Protocol No. 11/I/2020). Written informed consent was obtained from all the survey participants. Samples were anonymized, and privacy of individual participants was maintained.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized participant data are available with the authorsACE2Angiotensin-converting enzyme 2CCMBCentre for Cellular & Molecular BiologyCIConfidence IntervalCOVID-19Coronavirus DiseaseCOICutoff indexCSIRCouncil of Scientific and Industrial ResearchGHMCGreater Hyderabad Municipal CorporationICMRIndian Council of Medical ResearchNINNational Institute of NutritionODKOpen Data KitRT-PCRReverse transcription polymerase chain reactionSARSSevere Acute Respiratory SyndromeSDStandard DeviationSPSSStatistical Package for the Social Sciences ER -